Studies how genes affect leflunomide response in rheumatoid arthritis
Studies whether gene variants relate to leflunomide benefit and side effects in rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis
Key facts
- Where
- Islamabad and Rawalpindi, PakistanSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 65 years old?
Source: NCT07388407, who can take part
Where in Pakistan
- Shifa International HospitalIslamabad, PakistanNo longer taking part
- Fauji Foundation Hospital, RawalpindiRawalpindi, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Foundation University Islamabad
- Trial code
- NCT07388407
- Record updated
- 5 February 2026
- Original description
1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent. 2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled. 3. DNA will be extracted in the laboratory, and SNP will be identified. 4. The efficacy and toxicity data will be studied against the SNPs found 5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.Read full original descriptionShow less
Pharmacogenetics of Leflunomide in the RA Management
1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent. 2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled. 3. DNA will be extracted in the laboratory, and SNP will be identified. 4. The efficacy and toxicity data will be studied against the SNPs found 5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.
Inclusion: At baseline, all patients should fulfill the revised ACR/EULAR criteria for RA10; Pakistani individuals; between ages of 20-75 years; New cases started on Leflunomide/ those already taking for less than a month and their biochemical and clinical data is available.
Exclusion: Cognitive impairment, neurological disease; Patients having inflammatory bowel disease/ Irritable bowel syndrome; Patients with active infective diseases -Patients who fail to complete 3 months of leflunomide therapy-; Patients below the age of 20; Patients not willing to participate/ consent not given; Non- Pakistani origin; Taking another DMARD simultaneously; Compromised renal and hepatic functions; Pregnant/ lactating patients.